:: Library Catalog

Copertina

Salvato in:

Dettagli Bibliografici
Autori principali:	Louis Talay, Matt Vickers
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15607
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
di: Yu‐Nan Huang, et al.
Pubblicazione: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
di: Yunwen Xu, et al.
Pubblicazione: (2025)

Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
di: Mona Abdel‐Bary, et al.
Pubblicazione: (2025)

Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
Pubblicazione: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
di: David C. Klonoff, et al.
Pubblicazione: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
di: Darren Lau, et al.
Pubblicazione: (2024)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
di: Irl B. Hirsch, et al.
Pubblicazione: (2024)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
di: Jessica Van Laren, et al.
Pubblicazione: (2026)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
di: Yi‐Chang Chou, et al.
Pubblicazione: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
di: Robert L. Dubin, et al.
Pubblicazione: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
di: Filip K. Knop, et al.
Pubblicazione: (2024)

Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice
di: Qilong Zhang, et al.
Pubblicazione: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
di: Karen L. Jones, et al.
Pubblicazione: (2024)

Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
di: Chia‐Ming Lin, et al.
Pubblicazione: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
di: Hans Johnson, et al.
Pubblicazione: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
di: Fu‐Shun Yen, et al.
Pubblicazione: (2025)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
di: Muhammad Aaqib Shamim, et al.
Pubblicazione: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
di: Iskandar Idris
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
di: Amanda R. Purcell, et al.
Pubblicazione: (2025)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
di: Ruoyang Jiao, et al.
Pubblicazione: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
di: Tae Hyeon Kim, et al.
Pubblicazione: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
di: Jason M. Samuels, et al.
Pubblicazione: (2024)

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
di: Carel W. le Roux, et al.
Pubblicazione: (2024)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial
di: Kelli M. Richardson, et al.
Pubblicazione: (2025)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
di: Stephanie L. Samuels, et al.
Pubblicazione: (2024)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
di: Gaspar R. Chiappa, et al.
Pubblicazione: (2026)

Ten‐year progression of obesity‐related complications in a population with overweight and obesity in the UK : A retrospective open cohort study
di: Jonathan Pearson‐Stuttard, et al.
Pubblicazione: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
di: Julio Rosenstock, et al.
Pubblicazione: (2025)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
di: Conner E. Johnson, et al.
Pubblicazione: (2024)

Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
di: Faisal I. Almohaileb, et al.
Pubblicazione: (2025)

The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism
di: Sarah V. Applebey, et al.
Pubblicazione: (2025)

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
di: Neeta B. Amin, et al.
Pubblicazione: (2024)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
di: Donna Shu‐Han Lin, et al.
Pubblicazione: (2024)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
di: Lucas Duchemin, et al.
Pubblicazione: (2025)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
di: Jincheng Shen, et al.
Pubblicazione: (2025)

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
di: Raffaele Napoli, et al.
Pubblicazione: (2024)

Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients
di: Louis Talay, et al.
Pubblicazione: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
di: Iskandar Idris
Pubblicazione: (2024)

Exploring population and sex‐specific disease trajectories for multimorbidities among individuals with overweight or obesity: A retrospective cohort study in UK biobank
di: Qianhui Lu, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
di: Lucas A. Mavromatis, et al.
Pubblicazione: (2025)